A Phase II Clinical Study to Evaluate the Efficacy and Safety of Hypofractionated Radiotherapy Combined with Granulocyte-Macrophage Colony-Stimulating Factor, Pomalidomide and Glofitamab in Patients with Newly Diagnosed Primary Central Nervous System Diffuse Large B-Cell Lymphoma (ChiCTR) - Oct 16, 2026 - P2 | N=24 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
New P2 trial • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Central Nervous System Lymphoma • CD20
|